



## Serum ferritin levels in patients with non-elevated Proton-Density Fat Fraction-derived R2\* Liver Iron Concentration – an exploratory study of Revita-2 phase II trial data –

<u>Manil D Chouhan</u><sup>1</sup>, Naomi Sakai<sup>1</sup>, Francisco Torrealdea<sup>2</sup>, Harith Rajagopalan<sup>3</sup>, Kelly White<sup>3</sup>, Vijeta Bhambhani<sup>3</sup>, Juan-Carlos Lopez Talavera<sup>3</sup>, Alan Bainbridge<sup>2</sup>, Stuart A Taylor<sup>1</sup>.

- 1. UCL Centre for Medical Imaging, University College London, London, UK
- 2. Department of Medical Physics, University College London Hospitals, UK
- 3. Fractyl Laboratories Inc., Lexington, MA, USA







- Fernández-Real, J. M. & Manco, M. Effects of iron overload on chronic metabolic diseases. Lancet Diabetes Endocrinol. 2, 513–526 (2014)
  - Taher et al. Correlation of liver iron concentration determined by R2 magnetic resonance imaging with serum ferritin in patients with thalassemia intermedia. Haematologica 2008 93: 1584-1586.





- T2\* maps are generated as part of the PDFF measurements and can be used to estimate liver iron concentration (LIC).
- Vendor-derived PDFF sequences (e.g. Philips mDixonQuant, GE IDEAL-IQ) enable multi-site, multi-vendor, multi-field strength studies







 DMR catheter is designed to perform submucosal lift and hydrothermal ablation of hyperplastic duodenal mucosa, promote healthy epithelial regrowth within 12 weeks, and reduce insulin resistance and hyperinsulinemia<sup>1,2</sup>





1. Hadefi A et al., *Dig Dis*. 2018;36:322-324.2. Rajagopalan H et al., *Diabetes Care*. 2016. 3. Cherrington A et al., *Gastrointest Endoscopy Clin N Am*. 2017;27:299-311. 4. Van Baar A et al., *Gut*. 2019; pii: gutjnl-2019-318349. 5. Haidry R et al., *GIE*. 2019; 673 - 681.e2. 6. van Baar ACG et al., DTM 2019 poster VAN 19122D. REVITA-2 NCT02879383; DMR = duodenal mucosal resurfacing; NAFLD = nonalcoholic fatty liver disease; NASH = nonalcoholic steatohepatitis; T2D = type 2 diabetes.





- DMR is a well-tolerated procedure with few, self-limited side effects<sup>3-5</sup>
- Prior studies (eg, REVITA-1) showed a single DMR procedure durably improves hepatic and glycemic parameters through 2 years in patients with T2D, indicating potential benefit in T2D with concomitant NAFLD/NASH<sup>3-6</sup>





1. Hadefi A et al., *Dig Dis*. 2018;36:322-324.2. Rajagopalan H et al., *Diabetes Care*. 2016. 3. Cherrington A et al., *Gastrointest Endoscopy Clin N Am*. 2017;27:299-311. 4. Van Baar A et al., *Gut*. 2019; pii: gutjnl-2019-318349. 5. Haidry R et al., *GIE*. 2019; 673 - 681.e2. 6. van Baar ACG et al., DTM 2019 poster VAN 19122D. REVITA-2 NCT02879383; DMR = duodenal mucosal resurfacing; NAFLD = nonalcoholic fatty liver disease; NASH = nonalcoholic steatohepatitis; T2D = type 2 diabetes.



Revita-2 is a phase II blinded, sham-controlled international multisite multi-scanner vendor cross-over trial (NCT02879383).

- Investigation of the effect of DMR on hepatic and glycaemic parameters in patients with sub-optimally controlled T2D across 7 sites (5 in EU, 2 in Brazil)
- Trial endpoints include absolute and relative change in liver MRI-PDFF from baseline at 12 weeks (in patients with MRI-PDFF >5% at baseline)







To investigate the relationship between serum ferritin levels and *non-elevated* proton-density fat fraction (PDFF) derived R2\* liver iron concentration (LIC) in patients with T2DM undergoing endoscopic Duodenal Mucosal Resurfacing (DMR).







 Vendor-derived PDFF sequences (e.g. Philips mDixonQuant, GE IDEAL-IQ) were used for multi-site, multivendor, multi-field strength studies



Parameter	Philips	GE
PDFF manufacturer-supplied package	mDixon Quant	IDEAL IQ
Sequence variant	3D Spoiled Gradient Echo	3D Spoiled Gradient Echo
Imaging Time	Breath-hold (< 20s)	Breath-hold (< 20s)
3D Slab dimensions*	40 Axial slices	40 Axial Slices
	FH – 240 mm	FH – 240 mm
	RL – 400 mm	Freq FoV: 400 mm
	AP – 350 mm	Phase FoV: 0.88
Voxel Dimensions	6 mm axial slices	6 mm axial slices
	2-2.5 mm isotropic in plane	2-2.5 mm isotropic in plane
TR	Shortest (5-10 ms)	Shortest (5-10 ms)
Number of echoes	6	6
TE of first echo	Shortest (~1-2ms)	Shortest (~1-2ms)
Echo spacing	Shortest (~1-2ms)	Shortest (~1-2ms)
Flip Angle	3 degrees	3 degrees
Parallel Imagaing Factor	2	2
Number of averages	1	0.5
Number of shots	-	2
Reconstructed images	Fat-only image	Fat-only image
	Water-only image	Water-only image
	PDFF map	PDFF map
	T2* map	T2* map







- Circular ROIs measuring upto 20mm diameter
- Colocalised on PDFF maps and T2\* maps
- LIC (µmol/g) estimated from T2\* data as previously<sup>1</sup>
- Absolute and relative (% of baseline) within-subject change in liver FF and LIC were assessed
- 1. Paisant, A., d'Assignies, G., Bannier, E., Bardou-Jacquet, E. & Gandon, Y. MRI for the measurement of liver iron content, and for the diagnosis and follow-up of iron overload disorders. Press. Medicale 46, e279–e287 (2017).





#### **Results – Study cohort**

# <sup>A</sup>UCL

9/14

### Baseline and 12-week post-treatment liver MRI scans with paired serum ferritin levels for

initial open-label training (n=17) cohort

DMR (n=39) cohort

Sham (n=23) cohort







10/14





- At baseline, a modest positive but significant correlation was demonstrated between LIC and serum ferritin
- All LIC measurements were <32 µmol/g consistent with normal (non-elevated liver iron)<sup>1,2</sup>



1. Labranche R, Gilbert G, Cerny M, et al. Liver Iron Quantification with MR Imaging: A Primer for Radiologists. *RadioGraphics*. 2018;38(2):392–412.

2. St. Pierre TG, Clark PR, Chua-Anusorn W, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. *Blood*. 2005;105(2):855–861.)



<u>Open-label training cohort (n=17) – change in serum ferritin vs change</u> in LIC 12 weeks post-treatment



-50

-100

(∎m o l/g)

2

(ng/m

rritin

- 2

LIC

Seru





### <u>DMR cohort (n=39) – change in serum ferritin vs change in LIC 12 weeks</u> <u>post-treatment</u>

r = 0.1075, P = 0.5146





<u>Sham treatment cohort (n=23) – change in serum ferritin vs change in LIC</u> 12 weeks post-treatment







- Even at non-elevated LIC levels, serum ferritin and LIC are positively correlated.
- Poor correlations in LIC and serum ferritin in post-treatment changes may reflect mechanistic effects on hepatic iron metabolism as a result of DMR.

